Outcome of patients treated with docetaxel versus paclitaxel in a non-randomized phase IV trial of first-line taxane/trastuzumab therapy in patients with HER2+metastatic breast cancer (MBC)

被引：0
|
作者：
Reddy, JC [1 ]
Barker, C [1 ]
Lim, D [1 ]
Klein, PM [1 ]
机构：
[1] Genentech Inc, San Francisco, CA 94080 USA
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2004年 / 88卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S129 / S129
页数：1
相关论文
共 50 条
  • [1] Lapatinib (L) with weekly paclitaxel (P) as first-line therapy for patients (pts) with HER2+metastatic breast cancer (MBC)
    Jagiello-Gruszfeld, A.
    Tjulandin, Sergei S.
    Dobrovolskava, N.
    Manikhas, A.
    Pienkowski, T.
    Knott, A.
    DeSilvio, M.
    Oliva, C.
    CANCER RESEARCH, 2009, 69 (02) : 246S - 246S
  • [2] Predictors of survival in patients with HER2+metastatic breast cancer (MBC) treated with trastuzumab
    Olson, E. M.
    Najita, J. S.
    Sohl, J.
    Arnaout, A.
    Winer, E. P.
    Lin, N. U.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [3] Clinical outcomes of patients of different races in a phase IV community-based trial of first-line trastuzumab plus a taxane in HER2+ metastatic breast cancer (MBC).
    Reddy, JC
    Barker, CR
    Lim, D
    Klein, PM
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 65S - 65S
  • [4] Phase II trial of weekly docetaxel, vinorelbine, and trastuzumab in the first-line treatment of patients (pts) with HER2-positive metastatic breast cancer (MBC)
    Peacock, N. W.
    Infante, J. R.
    Yardley, D. A.
    Burris, H. A., III
    Greco, F. A.
    Farley, C.
    Webb, C.
    Spigel, D. R.
    Hainsworth, J. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [5] Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer: the JO17360 Trial Group
    Inoue, Kenichi
    Nakagami, Kazuhiko
    Mizutani, Mitsuhiro
    Hozumi, Yasuo
    Fujiwara, Yasuhiro
    Masuda, Norikazu
    Tsukamoto, Fumine
    Saito, Mitsue
    Miura, Shigeto
    Eguchi, Kenji
    Shinkai, Tetsu
    Ando, Masashi
    Watanabe, Toru
    Masuda, Noriyuki
    Ohashi, Yasuo
    Sano, Muneaki
    Noguchi, Shinzaburo
    BREAST CANCER RESEARCH AND TREATMENT, 2010, 119 (01) : 127 - 136
  • [6] Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer: the JO17360 Trial Group
    Kenichi Inoue
    Kazuhiko Nakagami
    Mitsuhiro Mizutani
    Yasuo Hozumi
    Yasuhiro Fujiwara
    Norikazu Masuda
    Fumine Tsukamoto
    Mitsue Saito
    Shigeto Miura
    Kenji Eguchi
    Tetsu Shinkai
    Masashi Ando
    Toru Watanabe
    Noriyuki Masuda
    Yasuo Ohashi
    Muneaki Sano
    Shinzaburo Noguchi
    Breast Cancer Research and Treatment, 2010, 119 : 127 - 136
  • [7] Randomized phase III study of trastuzumab monotherapy followed by docetaxel and trastuzumab versus the combination of trastuzumab and docetaxel as first-line treatment in patients with HER2 positive metastatic breast cancer
    Najagami, K.
    Inoue, K.
    Mizutani, M.
    Hozumi, Y.
    Fujiwara, Y.
    Masuda, N.
    Tsukamoto, F.
    Saito, M.
    Ohashi, Y.
    Sano, M.
    Noguchi, S.
    CANCER RESEARCH, 2009, 69 (02) : 241S - 242S
  • [8] Updated efficacy and safety assessment of first-line therapy with lapatinib, trastuzumab, and paclitaxel in HER2+metastatic breast cancer
    Esteva, F. J.
    Franco, S.
    Hagan, M. K.
    Brewster, A.
    Williams, W.
    Florance, A. M.
    Koch, K.
    Turner, S. J.
    Ridderheim, M.
    Perez, A. T.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [9] WEEKLY PACLITAXEL (PCT) plus TRASTUZUMAB (T) AS FIRST-LINE THERAPY OF PATIENTS (PTS) WITH HER-2/NEU POSITIVE METASTATIC BREAST CANCER (MBC): A MULTICENTER RANDOMIZED PHASE II TRIAL
    Gasparini, Giampietro
    Crivellari, Diana
    Filippelli, Gianfranco
    Morabito, Alessandro
    Silingardi, Vittorio
    De Sio, Livia
    Spada, Antonella
    Papaldo, Paola
    Carillio, Guido
    Veronesi, A.
    Zancan, Matelda
    Gion, Massimo
    Caputo, Antonio
    Cognetti, Francesco
    Amadori, Dino
    ANNALS OF ONCOLOGY, 2004, 15 : 27 - 27
  • [10] Phase II trial of trastuzumab and paclitaxel or docetaxel administered every 3 weeks to patients receiving a first treatment for HER2+metastatic breast cancer.
    Stewart, JA
    Fehrenbacher, L
    Blanchard, RA
    Rodriguez, GI
    Vogel, CL
    Anavekar, P
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 78S - 78S
12345